
Ayala Pharmaceuticals AYLA
Geschäftsbericht 2022
hinzugefügt 31.03.2023
Ayala Pharmaceuticals Operativer Cashflow 2011-2026 | AYLA
Operativer Cashflow Jährlich Ayala Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -34.5 M | -38.4 M | -27.5 M | -15 M | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -15 M | -38.4 M | -28.8 M |
Operativer Cashflow Vierteljährlich Ayala Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -26.3 M | -17 M | -9.98 M | - | -30.6 M | -21.2 M | -9.65 M | - | -20.6 M | -11.7 M | -6.39 M | - | -11.3 M | -6.1 M | -3.56 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -3.56 M | -30.6 M | -14.5 M |
Operativer Cashflow anderer Aktien in der Pharmaeinzelhändler
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M | ||
|
Burford Capital Limited
BUR
|
181 M | $ 4.78 | 1.38 % | $ 761 M | ||
|
Cabaletta Bio
CABA
|
-131 M | $ 3.35 | 2.61 % | $ 337 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-8.95 M | $ 3.08 | 0.98 % | $ 5.07 M | ||
|
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
524 M | $ 335.44 | -1.17 % | $ 43.9 B | ||
|
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.73 | 3.04 % | $ 8.97 B | ||
|
AlloVir
ALVR
|
-38.4 M | - | 4.14 % | $ 49.1 M | ||
|
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | ||
|
Aligos Therapeutics
ALGS
|
-82.5 M | $ 7.34 | -16.02 % | $ 72.6 M | ||
|
Allakos
ALLK
|
-116 M | - | - | $ 28.6 M | ||
|
Esperion Therapeutics
ESPR
|
-13.1 M | $ 2.08 | 1.22 % | $ 432 M | ||
|
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | ||
|
Evogene Ltd.
EVGN
|
-24.7 M | $ 0.83 | 1.6 % | $ 27.9 M | ||
|
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M | ||
|
Forte Biosciences
FBRX
|
-50.9 M | $ 32.17 | -0.77 % | $ 417 M | ||
|
Applied Therapeutics
APLT
|
-55.2 M | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
156 M | $ 21.38 | - | $ 999 M | ||
|
Galapagos NV
GLPG
|
-504 M | $ 29.04 | 0.55 % | $ 2.69 B | ||
|
Genmab A/S
GMAB
|
1.33 B | $ 29.21 | 0.5 % | $ 18.7 B | ||
|
GT Biopharma
GTBP
|
-12.9 M | $ 0.38 | -3.06 % | $ 2.1 M | ||
|
BioNTech SE
BNTX
|
890 M | $ 99.45 | 1.06 % | $ 27.2 B | ||
|
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | ||
|
Hoth Therapeutics
HOTH
|
-9.8 M | $ 0.7 | 7.77 % | $ 9.66 M | ||
|
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | ||
|
Harmony Biosciences Holdings
HRMY
|
348 M | $ 29.41 | 0.41 % | $ 1.69 B | ||
|
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
68 M | $ 1.55 | -0.96 % | $ 399 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | ||
|
ImmuCell Corporation
ICCC
|
2.48 M | $ 7.71 | -0.26 % | $ 69.6 M | ||
|
Aquestive Therapeutics
AQST
|
-52.4 M | $ 4.2 | 1.08 % | $ 449 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-5.62 M | $ 24.55 | -2.17 % | $ 3.12 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-6.98 M | - | -2.5 % | $ 5.88 M | ||
|
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | ||
|
BioDelivery Sciences International
BDSI
|
41 M | - | -4.8 % | $ 255 M | ||
|
Autolus Therapeutics plc
AUTL
|
-284 M | $ 1.47 | -1.01 % | $ 391 M | ||
|
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | ||
|
Immatics N.V.
IMTX
|
-81.8 M | $ 10.91 | -0.41 % | $ 686 M | ||
|
BeiGene, Ltd.
BGNE
|
1.13 B | - | 0.49 % | $ 251 B | ||
|
Incyte Corporation
INCY
|
1.41 B | $ 97.66 | -0.04 % | $ 19.1 B | ||
|
AVROBIO
AVRO
|
-63.2 M | - | 1083.1 % | $ 745 M |